Changing strategies for target therapy in gastric cancer

Table 2 Clinical trials with angiogenesis targeting agents

Study	n	Design	Line	Treatment	Primary end point	Results	P value
AVAGAST[59]	774	Phase 3, RCT	First	Bevacizumab + XP vs Placebo + XP	OS	HR = 0.87; 95%CI: 0.73-1.03	0.1002
REGARD[61]	355	Phase 3, RCT	Second	RAM vs Placeb	OS	HR = 0.81; 95%CI: 0.68-0.96	0.0470
RAINBOW[62]	665	Phase 3, RCT	Second	RAM + paclitaxel vs Placebo + paclitaxel	OS	HR = 0.81; 95%CI: 0.68-0.96	0.0170
Qin et al[63]	270	Phase 3, RCT	Third	Apatinib vs placebo	OS	HR = 0.71; 95%CI: 0.54-0.94	0.0160

RCT: Randomized controlled trial; XP: Capecitabine plus Cisplatin; RAM: Ramucirumab; OS: Overall survival.